Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

[Factors influencing the referral of nursing home patients to the hospital].

Huls M, Pouw MA, Nieuwenhuizen N, van Munster BC, de Rooij SE.

Tijdschr Gerontol Geriatr. 2018 Oct;49(5):167-173. doi: 10.1007/s12439-018-0260-x. Epub 2018 Sep 10. Dutch.

PMID:
30203244
2.

Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.

Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B, Forget MA, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJ.

J Clin Invest. 2016 Sep 1;126(9):3363-76. doi: 10.1172/JCI86721. Epub 2016 Aug 2.

3.

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System.

Kumaresan P, Figliola M, Moyes JS, Huls MH, Tewari P, Shpall EJ, Champlin R, Cooper LJ.

J Vis Exp. 2015 Oct 5;(104). doi: 10.3791/52808.

4.

Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.

Deniger DC, Yu J, Huls MH, Figliola MJ, Mi T, Maiti SN, Widhopf GF 2nd, Hurton LV, Thokala R, Singh H, Olivares S, Champlin RE, Wierda WG, Kipps TJ, Cooper LJ.

PLoS One. 2015 Jun 1;10(6):e0128151. doi: 10.1371/journal.pone.0128151. eCollection 2015.

5.

Learning to care for older patients: hospitals and nursing homes as learning environments.

Huls M, de Rooij SE, Diepstraten A, Koopmans R, Helmich E.

Med Educ. 2015 Mar;49(3):332-9. doi: 10.1111/medu.12646.

PMID:
25693992
6.

Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor.

Singh H, Moyes JS, Huls MH, Cooper LJ.

Cancer Gene Ther. 2015 Mar;22(2):95-100. doi: 10.1038/cgt.2014.69. Epub 2015 Jan 16. Review.

PMID:
25591810
7.

Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection.

Kumaresan PR, Manuri PR, Albert ND, Maiti S, Singh H, Mi T, Roszik J, Rabinovich B, Olivares S, Krishnamurthy J, Zhang L, Najjar AM, Huls MH, Lee DA, Champlin RE, Kontoyiannis DP, Cooper LJ.

Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10660-5. doi: 10.1073/pnas.1312789111. Epub 2014 Jul 7.

8.

Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.

Deniger DC, Maiti SN, Mi T, Switzer KC, Ramachandran V, Hurton LV, Ang S, Olivares S, Rabinovich BA, Huls MH, Lee DA, Bast RC Jr, Champlin RE, Cooper LJ.

Clin Cancer Res. 2014 Nov 15;20(22):5708-19. doi: 10.1158/1078-0432.CCR-13-3451. Epub 2014 May 15.

9.

Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood.

Huls MH, Figliola MJ, Dawson MJ, Olivares S, Kebriaei P, Shpall EJ, Champlin RE, Singh H, Cooper LJ.

J Vis Exp. 2013 Feb 1;(72):e50070. doi: 10.3791/50070.

10.

Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells.

Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, Singh H, Hurton L, Maiti SN, Huls MH, Champlin RE, Cooper LJ, Lee DA.

PLoS One. 2012;7(1):e30264. doi: 10.1371/journal.pone.0030264. Epub 2012 Jan 18.

11.

The Homo aurignaciensis hauseri from Combe-Capelle: a Mesolithic burial.

Hoffmann A, Hublin JJ, Hüls M, Terberger T.

J Hum Evol. 2011 Aug;61(2):211-4. doi: 10.1016/j.jhevol.2011.03.001. Epub 2011 Apr 12. No abstract available.

PMID:
21486678
12.

Deficiency of either P-glycoprotein or breast cancer resistance protein protect against acute kidney injury.

Huls M, Schoeber JP, Verfaillie CM, Luttun A, Ulloa-Montoya F, Menke AL, van Bolderen LR, Woestenenk RM, Merkx GF, Wetzels JF, Russel FG, Masereeuw R.

Cell Transplant. 2010;19(9):1195-208. doi: 10.3727/096368910X504478. Epub 2010 May 4.

PMID:
20977831
13.

Expression of aberrantly glycosylated Mucin-1 in ovarian cancer.

Van Elssen CH, Frings PW, Bot FJ, Van de Vijver KK, Huls MB, Meek B, Hupperets P, Germeraad WT, Bos GM.

Histopathology. 2010 Oct;57(4):597-606. doi: 10.1111/j.1365-2559.2010.03667.x.

PMID:
20955385
14.

Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.

Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, Huls MH, Sheehan A, Wu MF, Liu H, Gee A, Brenner MK, Rooney CM, Heslop HE, Gottschalk S.

J Immunother. 2010 Nov-Dec;33(9):983-90. doi: 10.1097/CJI.0b013e3181f3cbf4.

15.

St. John's Wort constituents modulate P-glycoprotein transport activity at the blood-brain barrier.

Ott M, Huls M, Cornelius MG, Fricker G.

Pharm Res. 2010 May;27(5):811-22. doi: 10.1007/s11095-010-0074-1. Epub 2010 Mar 13.

PMID:
20229133
16.

Osteoradionecrosis of tympanic bone: reconstruction of outer ear canal with pedicled skin flap, combined with hyperbaric oxygen therapy, in five patients.

Metselaar M, Dumans AG, van der Huls MP, Sterk W, Feenstra L.

J Laryngol Otol. 2009 Oct;123(10):1114-9. doi: 10.1017/S0022215109990612. Epub 2009 Jul 16.

PMID:
19607743
17.

Early hyperbaric oxygen therapy for reducing radiotherapy side effects: early results of a randomized trial in oropharyngeal and nasopharyngeal cancer.

Teguh DN, Levendag PC, Noever I, Voet P, van der Est H, van Rooij P, Dumans AG, de Boer MF, van der Huls MP, Sterk W, Schmitz PI.

Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):711-6. doi: 10.1016/j.ijrobp.2008.11.056. Epub 2009 Apr 20.

PMID:
19386439
18.

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.

Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK.

Nat Med. 2008 Nov;14(11):1264-70. doi: 10.1038/nm.1882. Epub 2008 Nov 2.

19.

Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.

Louis CU, Straathof K, Bollard CM, Gerken C, Huls MH, Gresik MV, Wu MF, Weiss HL, Gee AP, Brenner MK, Rooney CM, Heslop HE, Gottschalk S.

Blood. 2009 Mar 12;113(11):2442-50. doi: 10.1182/blood-2008-05-157222. Epub 2008 Oct 29.

20.

Surface Mucin-1 does not play a role in dendritic cell migration.

Cloosen S, Caberg JH, Huls MB, Vanderlocht J, Senden-Gijsbers BL, Roncarati P, Hubert P, Delvenne P, Germeraad WT, Bos GM.

Mol Immunol. 2009 Feb;46(4):738-42. doi: 10.1016/j.molimm.2008.07.033. Epub 2008 Oct 25.

PMID:
18952292
21.

The role of ATP binding cassette transporters in tissue defense and organ regeneration.

Huls M, Russel FG, Masereeuw R.

J Pharmacol Exp Ther. 2009 Jan;328(1):3-9. doi: 10.1124/jpet.107.132225. Epub 2008 Sep 12. Review.

PMID:
18791064
22.

Insights into the role of bone marrow-derived stem cells in renal repair.

Huls M, Russel FG, Masereeuw R.

Kidney Blood Press Res. 2008;31(2):104-10. doi: 10.1159/000121387. Epub 2008 Mar 20. Review.

23.

The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane.

Huls M, Brown CD, Windass AS, Sayer R, van den Heuvel JJ, Heemskerk S, Russel FG, Masereeuw R.

Kidney Int. 2008 Jan;73(2):220-5. Epub 2007 Oct 31.

24.

Triadin is a critical determinant of cellular Ca cycling and contractility in the heart.

Kirchhefer U, Klimas J, Baba HA, Buchwalow IB, Fabritz L, Hüls M, Matus M, Müller FU, Schmitz W, Neumann J.

Am J Physiol Heart Circ Physiol. 2007 Nov;293(5):H3165-74. Epub 2007 Sep 21.

25.

P-glycoprotein-deficient mice have proximal tubule dysfunction but are protected against ischemic renal injury.

Huls M, Kramers C, Levtchenko EN, Wilmer MJ, Dijkman HB, Kluijtmans LA, van der Hoorn JW, Russel FG, Masereeuw R.

Kidney Int. 2007 Nov;72(10):1233-41. Epub 2007 Sep 12.

26.

Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.

Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G, Khalil M, Wu MF, Huls MH, Chang CC, Gresik MV, Gee AP, Brenner MK, Rooney CM, Heslop HE.

Blood. 2007 Oct 15;110(8):2838-45. Epub 2007 Jul 3.

27.

Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.

Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, Carrum G, Krance RA, Chang CC, Molldrem JJ, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM.

Nat Med. 2006 Oct;12(10):1160-6. Epub 2006 Sep 24.

PMID:
16998485
28.

In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.

Bollard CM, Gottschalk S, Huls MH, Molldrem J, Przepiorka D, Rooney CM, Heslop HE.

Leuk Lymphoma. 2006 May;47(5):837-42.

PMID:
16753867
29.

Slc11a1 (formerly Nramp1) polymorphisms and susceptibility to post-transplant lymphoproliferative disease following pediatric liver transplantation.

Barshes NR, Lee TR, Goss JA, Goodpastor SE, Huls MH, Rooney CM, Karpen SJ, Wyllie S.

Transpl Infect Dis. 2006 Jun;8(2):108-12.

PMID:
16734634
30.

ABC transporter expression profiling after ischemic reperfusion injury in mouse kidney.

Huls M, van den Heuvel JJ, Dijkman HB, Russel FG, Masereeuw R.

Kidney Int. 2006 Jun;69(12):2186-93. Epub 2006 Apr 12.

31.

Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma.

Bollard CM, Huls MH, Buza E, Weiss H, Torrano V, Gresik MV, Chang J, Gee A, Gottschalk SM, Carrum G, Brenner MK, Rooney CM, Heslop HE.

Clin Lymphoma Myeloma. 2006 Jan;6(4):342-7. No abstract available.

PMID:
16507214
32.

T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients.

Leen AM, Myers GD, Bollard CM, Huls MH, Sili U, Gee AP, Heslop HE, Rooney CM.

Ann N Y Acad Sci. 2005 Dec;1062:104-15. Review.

PMID:
16461793
33.

Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.

Straathof KC, Leen AM, Buza EL, Taylor G, Huls MH, Heslop HE, Rooney CM, Bollard CM.

J Immunol. 2005 Sep 15;175(6):4137-47. Erratum in: J Immunol. 2005 Nov 1;175(9):6238.

34.

Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo.

Hanks BA, Jiang J, Singh RA, Song W, Barry M, Huls MH, Slawin KM, Spencer DM.

Nat Med. 2005 Feb;11(2):130-7. Epub 2005 Jan 23.

PMID:
15665830
35.

Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.

Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, Sixbey J, Gresik MV, Carrum G, Hudson M, Dilloo D, Gee A, Brenner MK, Rooney CM, Heslop HE.

J Exp Med. 2004 Dec 20;200(12):1623-33.

36.

Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes.

Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, Gresik MV, Gee AP, Russell HV, Brenner MK, Rooney CM, Heslop HE.

Blood. 2005 Mar 1;105(5):1898-904. Epub 2004 Nov 12.

37.

Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes.

Pakakasama S, Eames GM, Morriss MC, Huls MH, Rooney CM, Heslop HE, Krance RA.

Transplantation. 2004 Sep 15;78(5):755-7.

PMID:
15371682
38.

The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.

Bollard CM, Straathof KC, Huls MH, Leen A, Lacuesta K, Davis A, Gottschalk S, Brenner MK, Heslop HE, Rooney CM.

J Immunother. 2004 Jul-Aug;27(4):317-27.

PMID:
15235393
39.

Options for T-cell based therapies.

Heslop HE, Gottschalk SM, Bollard CM, Straathof KC, Huls MH, Brenner MK, Rooney CM.

Vox Sang. 2004 Jul;87 Suppl 2:230-4. Review. No abstract available.

PMID:
15209923
40.

Glyburide inhibits dipyridamole-induced forearm vasodilation but not adenosine-induced forearm vasodilation.

Bijlstra P, van Ginneken EE, Huls M, van Dijk R, Smits P, Rongen GA.

Clin Pharmacol Ther. 2004 Mar;75(3):147-56.

PMID:
15001965
41.

Prompt versus preemptive intervention for EBV lymphoproliferative disease.

Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA, Brenner MK, Rooney CM, Heslop HE.

Blood. 2004 May 15;103(10):3979-81. Epub 2004 Jan 29.

42.

A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.

Wagner HJ, Bollard CM, Vigouroux S, Huls MH, Anderson R, Prentice HG, Brenner MK, Heslop HE, Rooney CM.

Cancer Gene Ther. 2004 Feb;11(2):81-91.

PMID:
14685154
43.

Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease.

Huls MH, Rooney CM, Heslop HE.

Acta Haematol. 2003;110(2-3):149-53. Review.

PMID:
14583675
44.

Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15.

Wagner HJ, Sili U, Gahn B, Vigouroux S, Huls MH, Xie W, Vignali D, Brenner MK, Heslop HE, Rooney CM.

Cytotherapy. 2003;5(3):231-40.

PMID:
12850791
45.

Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy.

Sili U, Huls MH, Davis AR, Gottschalk S, Brenner MK, Heslop HE, Rooney CM.

J Immunother. 2003 May-Jun;26(3):241-56.

PMID:
12806278
46.

Immunotherapy for Hodgkin's disease.

Rooney CM, Bollard C, Huls MH, Gahn B, Gottschalk S, Wagner HJ, Anderson R, Prentice HG, Brenner MK, Heslop HE.

Ann Hematol. 2002;81 Suppl 2:S39-42.

PMID:
12611071
47.

Immune therapy for EBV infections after hemopoietic stem-cell transplant.

Heslop HE, Bollard CM, Gottschalk S, Kuehnle I, Huls MH, Gee AP, Brenner MK, Rooney CM.

Cytotherapy. 2002;4(5):433-4. Review. No abstract available.

PMID:
12473214
48.

Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.

Gottschalk S, Edwards OL, Sili U, Huls MH, Goltsova T, Davis AR, Heslop HE, Rooney CM.

Blood. 2003 Mar 1;101(5):1905-12. Epub 2002 Oct 31.

49.

Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection.

Savoldo B, Huls MH, Liu Z, Okamura T, Volk HD, Reinke P, Sabat R, Babel N, Jones JF, Webster-Cyriaque J, Gee AP, Brenner MK, Heslop HE, Rooney CM.

Blood. 2002 Dec 1;100(12):4059-66. Epub 2002 Aug 1.

50.

Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

Bollard CM, Rössig C, Calonge MJ, Huls MH, Wagner HJ, Massague J, Brenner MK, Heslop HE, Rooney CM.

Blood. 2002 May 1;99(9):3179-87.

Supplemental Content

Support Center